...
首页> 外文期刊>Oncology Research >Overexpression of LIMK1 promotes migration ability of multidrug-resistant osteosarcoma cells
【24h】

Overexpression of LIMK1 promotes migration ability of multidrug-resistant osteosarcoma cells

机译:LIMK1的过表达促进多药耐药骨肉瘤细胞的迁移能力

获取原文
获取原文并翻译 | 示例
           

摘要

Multidrug resistance (MDR) to chemotherapy is a major obstacle in the treatment of cancer and the resistance process is multifactorial. Studies on multidrug resistance mechanisms relied on the availability of cancer multidrug resistance cell lines that have been established. In this study we successfully established a multidrug resistance cell line MG63/VCR derived from human osteosarcoma cell line MG63 based on the induction by vincristine. MG63/VCR cells exhibited high resistance to vincristine and other anticancer drugs, accompanied by upregulated expression of MDR-associated genes MDR1, MRP1, and Bcl-2. Notably, we found that MG63/VCR cells exhibited higher migration ability compared to parental MG63 cells. Moreover, we demonstrated that LIMK1, a key regulator of actin cytoskeleton, was overexpressed at both mRNA and protein levels in MG63/VCR cells and the higher LIMK1 protein level was correlated with higher level of phosphorylated cofilin. In addition, knockdown of LIMK1 abolished the higher migration ability of MG63/ VCR cells. These results suggest that LIMK1 overexpression contributes to the invasion and metastasis of drug-resistant osteosarcoma and reveal LIMK as a novel therapeutic target for drug resistant osteosarcoma.
机译:化疗的多药耐药性(MDR)是癌症治疗的主要障碍,耐药过程是多因素的。对多药耐药机制的研究依赖于已建立的癌症多药耐药细胞系的可用性。在这项研究中,我们基于长春新碱的诱导成功建立了源自人骨肉瘤细胞株MG63的多药耐药细胞株MG63 / VCR。 MG63 / VCR细胞对长春新碱和其他抗癌药物表现出高抗性,并伴有与MDR相关的基因MDR1,MRP1和Bcl-2的表达上调。值得注意的是,我们发现与亲代MG63细胞相比,MG63 / VCR细胞表现出更高的迁移能力。此外,我们证明了LIMK1是肌动蛋白细胞骨架的关键调节因子,在MG63 / VCR细胞的mRNA和蛋白水平上均过表达,而更高的LIMK1蛋白水平与磷酸化的cofilin水平相关。此外,敲低LIMK1消除了MG63 / VCR细胞更高的迁移能力。这些结果表明LIMK1过表达有助于耐药性骨肉瘤的侵袭和转移,并揭示LIMK作为耐药性骨肉瘤的新型治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号